Fig. 2From: A phase IA dose-escalation study of PHI-101, a new checkpoint kinase 2 inhibitor, for platinum-resistant recurrent ovarian cancerAccelerated dose escalation and switching to standard 3+3 dose escalation scheme.Back to article page